Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review

Monoclonal antibody inhibitors of the epidermal growth factor receptor (EGFR) have been shown to improve outcomes for patients with metastatic colorectal cancer (mCRC) without RAS gene mutations. However, treatment with anti-EGFR agents can be associated with toxicities of the skin, nails, hair, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacouture, Mario E., Anadkat, Milan, Jatoi, Aminah, Garawin, Tamer, Bohac, Chet, Mitchell, Edith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773267/
https://www.ncbi.nlm.nih.gov/pubmed/29576427
http://dx.doi.org/10.1016/j.clcc.2017.12.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773267/
https://www.ncbi.nlm.nih.gov/pubmed/29576427
http://dx.doi.org/10.1016/j.clcc.2017.12.004

Ejemplares similares